Free Trial
NASDAQ:CALT

Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Calliditas Therapeutics AB (publ) logo
$40.00 0.00 (0.00%)
As of 03/27/2025

About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)

Key Stats

Today's Range
$40.00
$40.00
50-Day Range
$40.00
$40.00
52-Week Range
$15.25
$43.00
Volume
N/A
Average Volume
10,339 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.25
Consensus Rating
Hold

Company Overview

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Remove Ads
Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

CALT Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

CALT Stock Analysis - Frequently Asked Questions

Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the beginning of 2025. Since then, CALT shares have increased by 0.0% and is now trading at $40.0001.
View the best growth stocks for 2025 here
.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09. The firm earned $52.36 million during the quarter, compared to analysts' expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 30.18% and a negative trailing twelve-month return on equity of 212.04%.

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an IPO on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager.

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX).

Company Calendar

Last Earnings
8/13/2024
Today
3/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CALT
Fax
N/A
Employees
180
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$39.25
High Stock Price Target
$40.00
Low Stock Price Target
$39.00
Potential Upside/Downside
-1.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-43,960,000.00
Pretax Margin
-29.40%

Debt

Sales & Book Value

Annual Sales
$1.60 billion
Price / Cash Flow
N/A
Book Value
$1.06 per share
Price / Book
37.74

Miscellaneous

Free Float
29,135,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
1.77

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CALT) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners